(Q38068736)

28 August 2017

1 reference

title

Lenalidomide alone and in combination for chronic lymphocytic leukemia (English)

1 reference

28 August 2017

0 references

Christine I Chen

1

1 reference

28 August 2017

publication date

1 March 2013

1 reference

Current hematologic malignancy reports

28 August 2017

published in

1 reference

28 August 2017

volume

8

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

7-13

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-012-0146-x

28 August 2017

exact match

0 references

cites work

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Immunomodulating drugs for chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0146-X

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

21 January 2018

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner

1 reference

PubMed

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

PubMed

12 December 2020

10.1007/S11899-012-0146-X

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1026225680

0 references

1 reference